ClinicalTrials.gg
Enrolling by invitationNCT07587775Updated Jul 23, 2026

The Effect of Osteoporotic Medications on Vertebral Bone Quality Score

A Phase 2 interventional study of Abaloparatide in Lumbar Degenerative Disease, sponsored by State University of New York at Buffalo. Enrolling by invitation at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by State University of New York at Buffalo · Phase 2, Interventional, and Treatment

How we know · 3 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 481 studies in Osteoporosis with a site in United States — 26 open to participants now, 36 under way, none of them phase 3. Osteoporosis · United States.

Planned enrollment
211th of 374
60 · median 73
Started
2026
with 7 others
Phase 2
73 of 481
2 open now
Primary completion
2028-06
later than 24 of 34 live
Registered
478th of 481
by date

Among the 481 studies in Osteoporosis with a site in United States, this one is the 211th largest by planned enrollment of the 374 interventional ones that give a count, is one of 8 that started in 2026, is one of 73 in phase 2, reaches primary completion later than 24 of the 34 other live ones, and was the 478th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

26 of the 481 studies in Osteoporosis with a site in United States are open now. Recruiting first, the newest first:

20 more — sign in →

All 26 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 481 studies in Osteoporosis with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the change in VBQ score, T score, TBS, and Hounsfield Units (HU) after 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease. The main question[s] it aims to answer is:

Does abaloparatide improve bone density in these patients, as defined by VBQ score compared to traditional methods such as DEXA and Hounsfield Units Does abaloparatide reduce the incidence of postoperative mechanical complications, including adjacent segment disease, subsidence, and proximal junctional kyphosis (PKJ)?

Participants will undergo a presurgical assessments and trained in clinic on the subcutaneous application of abaloparatide. Prior to treatment, patients will have baseline assessments, including a lumbar MRI, DEXA scan, and lumbar CT. Post-surgically, participants will administer abaloparatide and return to clinic after 3-6 months for follow-up assessments including a new MRI, lumbar CT, and DEXA scan. Patients will be followed for up to 2 years postoperatively to identify complications such as adjacent segment disease, pseudarthrosis, failure of instrumentation, and PJK.

03

Conditions studied

  • Lumbar Degenerative Disease

Browse trials for

Keywords

  • Osteoporosis
  • Spinal Fusion
  • Lumbar Degenerative Disease
  • Abaloparatide
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Osteoporosis based on the following criteria:

    • Fragility fracture (low trauma fracture similar to a fall from a standing position except for fracture to the skull, face, fingers, and toes)
    • T score \<-2.5
    • T-score -1 to -2.5 with a high FRAX or high TBS adjusted FRAX (with a 10-year probability of major osteoporotic fracture ≥20% or a 10-year probability of hip fracture ≥3%)
  • Fulfill criteria for treatment with anabolic therapy, as outlined in the American Association of Clinical Endocrinologist guidelines for the diagnosis and treatment of osteoporosis in women and Evidence-Based Guideline for the management of osteoporosis in men.
  • Lumbar Degenerative Disease as evidenced by a diagnosis of spondylosis, spondylolisthesis, degenerative disc disease with spinal stenosis, and degenerative scoliosis
  • Have or be willing to have a DEXA scan, lumbar MRI, and lumbar CT within 3 months of the start of Abaloparatide
  • If on thyroid hormone replacement, having been on it for at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Previous lumbar surgery
  • Past medical history of: sarcoma, including osteosarcoma, paget disease or other skeletal , unexplained elevations of alkaline phosphatase, prior external beam radiation, and pre-existing hypercalcemia
  • Diagnosis of secondary osteoporosis
  • Vitamin D deficit
  • History of prior treatment with TPTD and ABL
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Abaloparatide

    3-6 months of self-administered abaloparatide in osteoporotic patients will undergo spinal fusion and decompression for lumbar degenerative disease

    Drug: Abaloparatide

Interventions

  • 3-6 months of treatment with abaloparatide in osteoporotic patients who will undergo spinal fusion and decompression for lumbar degenerative disease

06

What researchers measure

Primary outcomes

  1. Improvement in Bone Quality

    Improvement in bone quality, using Vertebral Bone Quality

    Time frame: 6 weeks post-op

  2. Improvement in Bone Quality

    Improvement in bone quality, using Hounsfield Units

    Time frame: 6 weeks post-op

  3. Improvement in Bone Quality

    Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)

    Time frame: 6 weeks post-op

  4. Improvement in Bone Quality

    Improvement in bone quality, using Vertebral Bone Quality

    Time frame: 6 months post-op

  5. Improvement in Bone Quality

    Improvement in bone quality, using Hounsfield Units

    Time frame: 6 months post-op

  6. Improvement in Bone Quality

    Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)

    Time frame: 6 months post-op

  7. Improvement in Bone Quality

    Improvement in bone quality, using Vertebral Bone Quality

    Time frame: 12 months post-op

  8. Improvement in Bone Quality

    Improvement in bone quality, using Hounsfield Units

    Time frame: 12 months post-op

  9. Improvement in Bone Quality

    Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)

    Time frame: 12 months post-op

  10. Improvement in Bone Quality

    Improvement in bone quality, using Vertebral Bone Quality

    Time frame: 24 months post-op

  11. Improvement in Bone Quality

    Improvement in bone quality, using Hounsfield Units

    Time frame: 24 months post-op

  12. Improvement in Bone Quality

    Improvement in bone quality, using DEXA (Dual-Energy X-ray ABsorptiometry)

    Time frame: 24 months post-op

Secondary outcomes

  1. Surgical Complications

    Presence of complications associated with fusion, such as Proximal Junctional Kyphosis (PJK), proximal junctional failure (PJF), pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.

    Time frame: 6 weeks post-operatively

  2. Surgical Complications

    Presence of complications associated with fusion, such as PJK, PJF, pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.

    Time frame: 6 months post-operatively

  3. Surgical Complications

    Presence of complications associated with fusion, such as PJK, PJF, pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.

    Time frame: 12 months post-operatively

  4. Surgical Complications

    Presence of complications associated with fusion, such as PJK, PJF, pseudoarthrosis, subsidence, adjacent segment disease, mechanical failure, reoperation, and patient-reported outcomes.

    Time frame: 24 months post-operatively

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — No individual participant data will be shared with other researchers. At the close of the study, statistical data may be shared but it will all be aggregated with outliers removed.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2028, 23 months after the start.

Of 33 non-industry phase 2 interventional studies under Osteoporosis, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 65. This study's planned 23 months is below that.

Counting every sponsor, half of 42 studies reached it within 47 months; a quarter within 29 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 2, 2026
First posted
May 14, 2026
StartActual
Jun 18, 2026
Primary completionEst.
Jun 1, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07587775
Responsible party
Jeffrey Mullin (Assistant Professor of Neurosurgery, State University of New York at Buffalo) — Principal investigator
First posted
May 14, 2026
Start date
Jun 18, 2026
Primary completion
Jun 1, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abaloparatide

Start the discussion